Get the Stockscreener App
19.69
5.63%
-1.15
Spyglass Pharma Inc stock is traded at $19.69, with a volume of 51,327.
It is down -5.63% in the last 24 hours and down -16.38% over the past month.
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.
See More
Previous Close:
$20.84
Open:
$20.84
24h Volume:
51,327
Relative Volume:
0.55
Market Cap:
$655.46M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-7.23%
1M Performance:
-16.38%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$19.45
$21.61
1-Week Range:
$19.45
$23.61
52-Week Range:
$19.45
$30.56
Spyglass Pharma Inc Stock (SGP) Company Profile
Name
Spyglass Pharma Inc
Sector
Industry
Phone
949-284-6904
Address
27081 ALISO CREEK ROAD, ALISO VIEJO
Compare SGP vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SGP
Spyglass Pharma Inc
|
19.61 | 696.75M | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
436.73 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
636.41 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
809.12 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
296.72 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.74 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Spyglass Pharma Inc Stock (SGP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-10-26 | Initiated | H.C. Wainwright | Buy |
| Mar-03-26 | Initiated | Citigroup | Buy |
| Mar-03-26 | Initiated | Jefferies | Buy |
| Mar-03-26 | Initiated | Leerink Partners | Outperform |
| Mar-03-26 | Initiated | Stifel | Buy |
Spyglass Pharma Inc Stock (SGP) Latest News
Spyglass Pharma (SGP) Stock Chart and Price History 2026 $SGP - MarketBeat
SpyGlass Pharma to Participate in Upcoming Investor Conferences - The Manila Times
SpyGlass Pharma execs set for three June healthcare investor events - Stock Titan
SpyGlass Pharma: New add-on CPT code supports BIM-IOL System - Eyes On Eyecare
SpyGlass Secures Billing Code for IOL Platform - Orange County Business Journal
Spyglass Pharma IncBIM-Iol System Phase 3 Trial Enrollment Expected To Complete In 2027 - TradingView
Eye surgeons get new code for implant treating glaucoma during cataract surgery - Stock Titan
Spyglass Pharma (SGP) Earnings Date and Reports 2026 $SGP - MarketBeat
SpyGlass Pharma (SGP) Q1 2026 Earnings Miss by Significant: Key TakeawaysBuyback Authorization - newser.com
SpyGlass Pharma posts Q1 loss as Phase 3 trials advance By Investing.com - Investing.com South Africa
SpyGlass Pharma posts Q1 loss as Phase 3 trials advance - Investing.com India
SpyGlass Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates - Sahm
Number of shareholders of SpyGlass Pharma, Inc. – NASDAQ:SGP - TradingView
SpyGlass Pharma (SGP) boosts cash to $251M after IPO while losses widen - Stock Titan
SpyGlass Pharma (SGP) boosts cash with IPO and reports strong BIM-IOL glaucoma data - Stock Titan
SpyGlass Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Spyglass Pharma (SGP) Institutional Ownership 2026 $SGP - MarketBeat
Eye implant ended IOP-lowering drops for 98% in trial - Stock Titan
SGP SpyGlass Pharma reports solid late-stage trial progress, lays out aggressive commercial expansion plans for 2025.Stock Community Signals - newser.com
What fair value gap SpyGlass Pharma (SGP)? (Buying Pressure) 2026-05-01Verified Stock Signals - Newser
SGP Ownership | SPYGLASS PHARMA INC (NASDAQ:SGP) - ChartMill
Eye care firm SpyGlass Pharma soars 65% in trading debut - MSN
SGP Technical Analysis | Trend, Signals & Chart Patterns | SPYGLASS PHARMA INC (NASDAQ:SGP) - ChartMill
All News for SGP : SpyGlass Pharma, Inc. - Zacks Investment Research
Dividend HistorySpyGlass Pharma, Inc. (SGP) - Zacks Investment Research
Is SpyGlass Pharma (SGP) Stock Good for Long Term | Price at $22.30, Down 0.71%Social Buy Zones - Newser
SpyGlass Pharma, Inc.: Fundamental Analysis and Financial Ratings | SGP | US85220G1094 - marketscreener.com
SGP: SpyGlass Pharma, Inc.Insider Transations - Zacks Investment Research
SpyGlass Pharma, Inc. (SGP) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
SpyGlass Pharma Reports Fourth Quarter and Full-Year 2025 Results - VisionMonday.com
SpyGlass Pharma, Inc. (SGP) stock price, news, quote and history - Yahoo Finance UK
Stifel reiterates Buy on SpyGlass Pharma stock, $42 target By Investing.com - Investing.com Canada
Stifel reiterates Buy on SpyGlass Pharma stock, $42 target - Investing.com
SpyGlass Pharma’s BIM-IOL System: Transforming Glaucoma and Ocular Hypertension Treatment with Long-Acting Drug Delivery Solutions - Minichart
SpyGlass Pharma (NASDAQ: SGP) outlines long-acting glaucoma implant pipeline - Stock Titan
[8-K] SpyGlass Pharma, Inc. Reports Material Event - Stock Titan
97% stopped glaucoma drops in SpyGlass eye implant study - Stock Titan
New Glaucoma Treatment Uses Eye Implant for Three-Year Drug Delivery - University of Colorado Anschutz
SpyGlass Pharma, Inc.(NasdaqGS: SGP) added to S&P TMI Index - marketscreener.com
SGP Stock Price, News & Analysis - Stock Titan
SpyGlass Valued at $900M After IPO - Orange County Business Journal
Spyglass Pharma (SGP) Insider Trading Activity 2026 $SGP - MarketBeat
Spyglass Pharma (NASDAQ:SGP) Coverage Initiated by Analysts at HC Wainwright - Defense World
H.C. Wainwright initiates SpyGlass Pharma stock coverage with buy rating By Investing.com - Investing.com Canada
SpyGlass Pharma reports positive 12-month Phase 1/2 BIM-IOL results with high drop-free rates - TradingView
SpyGlass Pharma reports positive 12-month glaucoma device trial data - Investing.com Australia
Spyglass Pharma Inc Stock (SGP) Financials Data
There is no financial data for Spyglass Pharma Inc (SGP). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Spyglass Pharma Inc Stock (SGP) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Behbahani Ali | Director |
Feb 09 '26 |
Buy |
16.00 |
937,500 |
15,000,000 |
6,035,038 |
| Florence Anthony A. Jr. | 10% Owner |
Feb 09 '26 |
Buy |
16.00 |
937,500 |
15,000,000 |
6,035,038 |
| BASKETT FOREST | 10% Owner |
Feb 09 '26 |
Buy |
16.00 |
937,500 |
15,000,000 |
6,035,038 |
| New Enterprise Associates 17, | 10% Owner |
Feb 09 '26 |
Buy |
16.00 |
937,500 |
15,000,000 |
6,035,038 |
| Yang Rick | 10% Owner |
Feb 09 '26 |
Buy |
16.00 |
937,500 |
15,000,000 |
6,035,038 |
| Makhzoumi Mohamad | 10% Owner |
Feb 09 '26 |
Buy |
16.00 |
937,500 |
15,000,000 |
6,035,038 |
| SANDELL SCOTT D | 10% Owner |
Feb 09 '26 |
Buy |
16.00 |
937,500 |
15,000,000 |
6,035,038 |
| Chang Carmen | 10% Owner |
Feb 09 '26 |
Buy |
16.00 |
937,500 |
15,000,000 |
6,035,038 |
| Walker Paul Edward | 10% Owner |
Feb 09 '26 |
Buy |
16.00 |
937,500 |
15,000,000 |
6,035,038 |
| Mathers Edward T | 10% Owner |
Feb 09 '26 |
Buy |
16.00 |
937,500 |
15,000,000 |
6,035,038 |
2.25%
0.46%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):